A retrospective study to determine clinical use of adjuvant pertuzumab and neratinib in patients with early-stage HER2-positive breast cancer
Latest Information Update: 07 Jul 2021
Price :
$35 *
At a glance
- Drugs Neratinib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Antineoplastics
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 07 Jul 2021 New trial record
- 01 Jun 2021 Results published in the Breast Cancer Research and Treatment